A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma

CONCLUSION: In the MAIC, elranatamab was consistently associated with improved rates and depth of response and significantly longer PFS and OS versus PCT in LocoMMotion and MAMMOTH.PMID:38078866 | DOI:10.1080/03007995.2023.2277850

Source: Current Medical Research and Opinion - December 11, 2023 Category: Research Authors: Isha Mol Yannan Hu Thomas W LeBlanc Joseph C Cappelleri Haitao Chu Guido Nador Didem Aydin Alex Schepart Patrick Hlavacek Source Type: research